Abstract:Non‐nucleoside reverse transcriptase inhibitors (NNRTIs) have significantly impacted the HIV‐1 wild‐type due to their high specificity and superior potency. As well as different combinations of NNRTIs have been used on clinically approved combining highly active antiretroviral therapy (HAART) to resist the growth of HIV‐1 and decrease the mortality rate of HIV/AIDS. Although the feeble strength against the drug‐resistant mutant strains and the long‐term damaging effects have been reducing the effectiveness of HAART, it could be a crucial challenge to develop novel Anti‐HIV leads with a vital mode of action and the least side effects. The extensive chemical reactivity and the diverse chemotherapeutic applications of the 1,3,5‐triazine have provided a wide scope of research in medicinal chemistry via a structural modification. In this review, we focused on the Anti‐HIV profile of the tri‐substituted s‐triazine derivatives with structure‐based features and also discussed the active mode of action to evaluate the significant findings. The tri‐substituted 1,3,5‐triazine derivatives have been found more promising to inhibit the growth of the drug‐sensitive and drug‐resistant variants of HIV‐1, especially HIV‐1 wild‐type, HIV‐1 K103N/Y181C, and HIV‐1 Tyr181Cys. It has been observed that these derivatives have interacted with the enzyme protein residues via a significant π ‐ π interaction and hydrogen bonding to resist the proliferation of the viral genomes. Further, the SAR and the active binding modes are critically described and highlight the role of structural variations with functional groups along with the binding affinity of targeted enzymes, which may be beneficial for rational drug discovery to develop highly dynamic Anti‐HIV agents.

Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update

Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

The latest developments in the design and discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV

Pyridin-2(1H)-ones as HIV-1 NNRTIs: a combinatorial optimization strategy

Development of Non-Nucleoside Reverse Transcriptase Inhibitors (nnrtis): Our Past Twenty Years

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

Development of Novel Dihydrofuro[3,4- d ]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C

Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV-1 NNRTIs

Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review

Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors (2019-2023)

Recent Progress in HIV-1 Inhibitors Targeting the Entrance Channel of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket

Druggability Modification Strategies of the Diarylpyrimidine‐type Non‐nucleoside Reverse Transcriptase Inhibitors

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs

Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses

Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains